Why is CLL refractory to bortezomib?

Blood

Volumn 112, Issue 9, 2008, Pages 3540-3541

  Wickremasinghe, Ranmohan Gitendra ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APIGENIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORIC ACID; BORONIC ACID DERIVATIVE; BORTEZOMIB; CHLORAMBUCIL; FLAVONOID; HYDROXYL GROUP; KAEMPFEROL; LACTACYSTIN; MG 262; MYRICETIN; PROTEASOME; QUERCETIN; UNCLASSIFIED DRUG;

APOPTOSIS; CELL KILLING; CHEMICAL REACTION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; LEUKEMIA CELL; MULTIPLE MYELOMA; MYELOMA CELL; NOTE; PLASMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 61849091373     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-171231     Document Type: Note

References (5)

1. Liu FT, Agrawal SG, Gribben J, et al. Bortezomib blocks Bax degradation in malignant B-cells during treatment with TRAIL. Blood. 2008;111:2797-2805.
2. Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer. 2006;107:916-924.
3. Chen D, Daniel KG, Chen MS, et al. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol. 2005;69:1421-1432.
4. RichardsonPG,Mitsiades C,HideshimaT,et al. Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005;4:290-296.
5. Jones DT, Ganeshaguru K, Anderson RJ, et al. Albumin activates the AKT signalling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. Blood. 2003;101:3174-3180.